<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05015153</url>
  </required_header>
  <id_info>
    <org_study_id>29BRC21.0093 (RAMBO)</org_study_id>
    <nct_id>NCT05015153</nct_id>
  </id_info>
  <brief_title>Impact on Quality of Life With Pulmonary RehAbilitation After Pulmonary eMBOlism: RAMBO Study</brief_title>
  <acronym>RAMBO</acronym>
  <official_title>Impact on Quality of Life With Pulmonary RehAbilitation After Pulmonary eMBOlism: RAMBO Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Brest</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Brest</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Pulmonary Embolism (PE) is a common and serious disease. Indeed, the annual incidence is&#xD;
      1/1000 patients per year and the 3-month mortality is 10%, which is twice that of myocardial&#xD;
      infarction. The treatment is based on anticoagulation for at least 3 months. However, after&#xD;
      three or six months of anticoagulation, persistent dyspnea and impairment of quality of life&#xD;
      are observed in at least 30% of cases. Several mechanisms explain dyspnea and impairment of&#xD;
      quality of life after PE, such as residual pulmonary artery obstruction, exercise&#xD;
      deconditioning, depressive syndrome or development of a cardio-respiratory pathology.&#xD;
      Pulmonary rehabilitation (PR) has been shown to be effective on dyspnea and quality of life&#xD;
      and is included in the therapeutic management of chronic respiratory diseases such as Chronic&#xD;
      Obstructive Pulmonary Disease (COPD) or pulmonary fibrosis. Furthermore, PR is also used&#xD;
      after a myocardial infarction. However, PR after PE is still not included in therapeutic&#xD;
      management of PE while outpatient management is recommended for the majority of patients&#xD;
      after an acute PE episode. Study hypothesis is that PR has the potential to improve quality&#xD;
      of life and dyspnea perception in patients who have received anticoagulation for at least 3&#xD;
      months after PE and who present an impairment of quality of life and/or a persistent dyspnea.&#xD;
      This study presents several innovative aspects. First, to our knowledge, This study is the&#xD;
      first large randomized trial assessing PR at least 3 months after acute symptomatic PE. Only&#xD;
      one small randomized trial on 18 patients evaluating the impact of PR after PE has been&#xD;
      published; as PR was performed just after the acute phase of PE in this trial, the clinical&#xD;
      status improvement observed in this study could not be explained by PR alone, but also by&#xD;
      anticoagulation. In this study, the investigators will include 112 patients at least 3 months&#xD;
      after PE in order to exclude the bias related to anticoagulation effect. Second, This study&#xD;
      is the first large randomized trial. Third, this study is the first that have the potential&#xD;
      to demonstrate efficacy and safety of delayed PR after PE in patients with impaired quality&#xD;
      of life due to persistent residual dyspnea.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">October 2021</start_date>
  <completion_date type="Anticipated">June 2025</completion_date>
  <primary_completion_date type="Anticipated">June 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Quality of life</measure>
    <time_frame>3 months</time_frame>
    <description>Pulmonary embolism Quality of life score. This score includes 6 items regarding the frequency of lung complaints, their intensity, their physical, personal, social and professional impact. For each item, an average score is collected</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety</measure>
    <time_frame>3 months</time_frame>
    <description>Number of events</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life</measure>
    <time_frame>15 months</time_frame>
    <description>Pulmonary embolism Quality of life score. This score includes 6 items regarding the frequency of lung complaints, their intensity, their physical, personal, social and professional impact. For each item, an average score is collected</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pulmonary Vascular Obstruction index</measure>
    <time_frame>3 months</time_frame>
    <description>Pulmonary Vascular Obstruction (Meyer score) assessed with V/Q lung scan</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of dyspnea</measure>
    <time_frame>3 months and 15 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of 6 Minutes Walk Test</measure>
    <time_frame>3 months and 15 months</time_frame>
    <description>6 Minutes Walk Test</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of Psychological status</measure>
    <time_frame>3 months and 15 months</time_frame>
    <description>Score of Hospital Anxiety and Depression scale. 14 rated items from 0 to 3. Seven questions relate to anxiety (total A) and seven others to the depressive dimension (total D), allowing thus obtaining two scores (maximum score for each score = 21)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Symptomatic recurrent PE</measure>
    <time_frame>15 months</time_frame>
    <description>Number of events</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Arterial thromboembolic events</measure>
    <time_frame>15 months</time_frame>
    <description>Number of events</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Deaths of all causes</measure>
    <time_frame>15 months</time_frame>
    <description>Number of events</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hospitalizations and acute medical events</measure>
    <time_frame>15 months</time_frame>
    <description>Number of events</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">112</enrollment>
  <condition>Pulmonary Embolism</condition>
  <condition>Quality of Life and Dyspnea</condition>
  <arm_group>
    <arm_group_label>Intervention group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>20 sessions of Pulmonary rehabilitation will be performed over a period of 3 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>No Pulmonary rehabilitation</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Pulmonary rehabilitation (PR)</intervention_name>
    <description>20 sessions of PR in respiratory rehabilitation centre will be performed over a period of 3 months</description>
    <arm_group_label>Intervention group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age ≥ 18 years&#xD;
&#xD;
          -  Patient treated with at least 3 months and up to 8 months of anticoagulation for&#xD;
             symptomatic EP diagnosed according the ESC and ACCP guidelines.&#xD;
&#xD;
          -  Patients who have a PembQol score ≥ 10% and whose total scores for the subgroups Q1&#xD;
             (dyspnea) and Q4 (impact of daily life) are ≥ 10%.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Presence of CTEPH according to international guidelines&#xD;
&#xD;
          -  Patients treated for acute PE with anticoagulants for more than 8 months&#xD;
&#xD;
          -  Active cancer or in remission for less than two years&#xD;
&#xD;
          -  Dyspnea post - COVID due to parenchymal injuries&#xD;
&#xD;
          -  Post-COVID hyperventilation syndrome without pulmonary vascular perfusion sequelae.&#xD;
&#xD;
          -  Physical or psychological inability to undertake PR&#xD;
&#xD;
          -  Isolated or more distal segmental PE&#xD;
&#xD;
          -  Neuro-muscular disease with PR contraindication.&#xD;
&#xD;
          -  Cardiac insufficiency (unstable coronary artery disease)&#xD;
&#xD;
          -  Severe respiratory failure (long-term oxygen therapy, pulmonary hypertension)&#xD;
&#xD;
          -  Chronic dyspnea MMRC ≥ 2 before PE&#xD;
&#xD;
          -  Cardiac or respiratory rehabilitation in the previous year&#xD;
&#xD;
          -  Indication to urgent PR within 6 months at the time of inclusion&#xD;
&#xD;
          -  Life expectancy of less than 12 months&#xD;
&#xD;
          -  Inability to give consent&#xD;
&#xD;
          -  Patient under guardianship or curatorship&#xD;
&#xD;
          -  Patient deprived of liberty by an administrative or judicial decision&#xD;
&#xD;
          -  Patient has not social security affiliation or who don't beneficiary of such social&#xD;
             security&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Cécile TROMEUR, PH</last_name>
    <phone>+33230337602</phone>
    <email>cecile.tromeur@chu-brest.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>CHU Angers</name>
      <address>
        <city>Angers</city>
        <zip>49100</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Frédéric GAGNADOUX, PU-PH</last_name>
    </contact>
    <investigator>
      <last_name>Frédéric GAGNADOUX, PU-PH</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Brest</name>
      <address>
        <city>Brest</city>
        <zip>29609</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Cécile TROMEUR, PH</last_name>
    </contact>
    <investigator>
      <last_name>Cécile TROMEUR, PH</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Francis COUTURAUD, PU-PH</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Aude BARNIER, PH</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Christophe GUT-GOBERT, PH</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Cécile L'HEVEDER, PH</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Christophe LEROYER, PU-PH</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Alexandre FAUCHE, PH</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Raphael LE MAO, PH</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHBS Lorient</name>
      <address>
        <city>Lorient</city>
        <zip>56100</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Mikael LE HENAFF, PH</last_name>
    </contact>
    <investigator>
      <last_name>Mikael LE HENAFF, PH</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CH Morlaix</name>
      <address>
        <city>Morlaix</city>
        <zip>29672</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Catherine LE BER, PH</last_name>
    </contact>
    <investigator>
      <last_name>Catherine LE BER, PH</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hegp (Ap-Hp)</name>
      <address>
        <city>Paris</city>
        <zip>75015</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Benjamin PLANQUETTE, PH</last_name>
    </contact>
    <investigator>
      <last_name>Benjamin PLANQUETTE, PH</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre de santé de Roscoff</name>
      <address>
        <city>Roscoff</city>
        <zip>29684</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Sophie RAMEL, PH</last_name>
    </contact>
    <investigator>
      <last_name>Sophie RAMEL, PH</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Saint-Etienne</name>
      <address>
        <city>Saint-Etienne</city>
        <zip>42055</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Laurent BERTOLETTI, PU-PH</last_name>
    </contact>
    <investigator>
      <last_name>Laurent BERTOLETTI, PU-PH</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Tours</name>
      <address>
        <city>Tours</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>August 11, 2021</study_first_submitted>
  <study_first_submitted_qc>August 18, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 20, 2021</study_first_posted>
  <last_update_submitted>August 18, 2021</last_update_submitted>
  <last_update_submitted_qc>August 18, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 20, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pulmonary Embolism</mesh_term>
    <mesh_term>Dyspnea</mesh_term>
    <mesh_term>Embolism</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>All collected data that underlie results in a publication</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_time_frame>Data will be available beginning five years and ending fifteen years following the final study report completion</ipd_time_frame>
    <ipd_access_criteria>Data access requests will be reviewed by the internal committee of Brest UH. Requestors will be required to sign and complete a data access agreement.</ipd_access_criteria>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

